Hualan Biological Engineering Inc
SZSE:002007

Watchlist Manager
Hualan Biological Engineering Inc Logo
Hualan Biological Engineering Inc
SZSE:002007
Watchlist
Price: 17.4 CNY -2.36% Market Closed
Market Cap: 31.7B CNY
Have any thoughts about
Hualan Biological Engineering Inc?
Write Note

Net Margin
Hualan Biological Engineering Inc

27.2%
Current
27%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
27.2%
=
Net Income
1.3B
/
Revenue
4.9B

Net Margin Across Competitors

Country CN
Market Cap 31.8B CNY
Net Margin
27%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.3B USD
Net Margin
9%
Country US
Market Cap 141.6B USD
Net Margin
13%
Country US
Market Cap 115.3B USD
Net Margin
0%
Country US
Market Cap 102.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 77.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 35.8B EUR
Net Margin
-14%
No Stocks Found

Hualan Biological Engineering Inc
Glance View

Market Cap
31.8B CNY
Industry
Biotechnology

Hualan Biological Engineering Inc., nestled in the heart of China, operates at the crossroads of innovation and health, focusing primarily on the production of vaccines and blood products. The company is at the forefront of a critical industry, ensuring the creation of products that play a pivotal role in maintaining public health. With a dedicated pursuit of scientific excellence, Hualan develops vaccines that protect against contagious diseases and specializes in plasma-derived therapeutics that have become a backbone in treating a variety of conditions requiring immune support or clotting factors. This dual focus not only showcases their expertise but also broadens their commercial portfolio, tapping into markets where demand is continually rising. Revenue streams for Hualan Biological are primarily driven by their deep penetration into domestic markets, where there is a growing emphasis on healthcare innovation and quality assurance. The company capitalizes on its research and development capabilities, which have enabled it to secure a strong pipeline of products and stay ahead in a competitive landscape. By leveraging its robust distribution network and quality manufacturing processes, Hualan ensures that its products reach hospitals and health institutions rapidly. This strategic orchestration of science and logistics allows Hualan not only to generate substantial revenues but also to reinforce its reputation as a leader within China's biopharmaceutical sector, ensuring it remains a vital contributor to public health initiatives.

Intrinsic Value
25.39 CNY
Undervaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
27.2%
=
Net Income
1.3B
/
Revenue
4.9B
What is the Net Margin of Hualan Biological Engineering Inc?

Based on Hualan Biological Engineering Inc's most recent financial statements, the company has Net Margin of 27.2%.